Aquestive Therapeutics Highlights Anaphylm Review, Launch Plans and $90.3M Cash Position

Aquestive Therapeutics reported FDA acceptance of Anaphylm's NDA resubmission with a March 2027 PDUFA goal date. The company plans regulatory filings in Canada and the EU by 2027. As of September 2026, cash reserves were $90.3 million, with up to $95 million in additional funding possible. A U.S. launch with 65-80 sales reps is planned if approved.

Original reporting
Published Nov 16, 2026, 11:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aquestive Therapeutics Highlights Anaphylm Review, Launch Plans and $90.3M Cash Position — source image
Decision brief

The 30-second read

$AQSTBullishMed
01

Why it matters

The FDA acceptance moves the product closer to market, potentially unlocking revenue and justifying the $90M cash position.

02

Market read

Regulatory milestone likely triggers short‑term buying interest and sets a timeline for future catalysts.

03

What to watch

The company still needs to secure additional funding and navigate foreign filings, which could delay commercialization.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Aquestive Therapeutics (AQST) is a clinical‑stage biotech developing Anaphylm for rare allergic conditions.

Company-level read

Ticker impact

$AQSTBullishHigh confidence
Context

FDA accepted Anaphylm's NDA resubmission and set a March 2027 PDUFA target, a material regulatory milestone for the company.

Expected impact

upward pressure as investors price in potential approval and future sales.

Evidence & confidence

An FDA acceptance is a key catalyst for biotech valuations; the market typically reacts positively to such milestones.

Market effects

May boost sentiment for the broader rare‑disease biotech sector.

Limited to U.S. biotech investors.

Minor, confined to specialty pharma space.

Counterpoint

If the FDA later requests additional data, the initial acceptance could be overstated.

Key entities

  • Aquestive Therapeutics

    Biotech firm developing Anaphylm.

  • FDA

    U.S. Food and Drug Administration.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

$AQSTMed

Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.